Dr. Julian Marschner

 

Publications

Reynders, M.; Willems, S.; Marschner, J. A.; Wein, T.; Merk, D.; Thorn-Seshold, O. A High-Quality Photoswitchable Probe that Selectively and Potently Regulates the Transcription Factor RORγ. Angew. Chem. Int. Ed., 2024. DOI

Nawa, F.; Sai, M.; Vietor, J.; Schwarzenbach, R.; Bitić, A.; Wolff, S.; Ildefeld, N.; Pabel, J.; Wein, T.; Marschner, J. A.; Heering, J.; Merk, D. Tuning RXR modulators for PGC1α recruitment. J. Med. Chem., 2024.  DOI

Isigkeit, L.; Hörmann, T.; Schallmayer, E.; Scholz, K.; Lillich, F.F.; Ehrler, J.H.M.; Hufnagel, B.; Büchner, J.; Marschner, J.A.; Pabel, J.; Proschak, E.; Merk, D. Automated design of multi-target ligands by generative deep learning. Nat. Commun., 2024, 15, 7946 DOI

Hank, E. C.; Sai, M.; Kasch, T.; Meijer, I.; Marschner, J. A.; Merk, D. Development of Tailless Homologue (TLX) Agonist Chemical Tools. J. Med. Chem., 2024. DOI

Willems, S.; Busch, R.; Nawa, F.; Ballarotto, M.; Lillich, F.; Kasch, T.; López-García, Ú.; Marschner, J. A.; Rüger, L.; Renelt, B.; Ohrndorf, J.; Arifi, S.; Zaienne, D.; Proschak, E.; Pabel, J.; Merk, D. Structural Optimization of Oxaprozin for Selective Inverse Nurr1 Agonism. J. Med. Chem., 2024, 67, 13324–13348. DOI

Sai, M.; Hank, E. C.; Lewandowski, M.; Kasch, T.; Marschner, J. A.; Merk, D. Development of Potent and Selective Nurr1 Agonists from Amodiaquine By Scaffold Hopping and Fragment Growing. Commun. Chem., 2024, 7, 149. DOI

Isigkeit, L.; Schallmayer, E.; Busch, R.; Brunello, L.; Tjaden, A.; Elson, L.; Müller, S.; Knapp, S.; Stolz, A.; Marschner, J. A.; Merk, D. Chemogenomics for NR1 nuclear hormone receptors. Nat. Commun., 2024, 15, 5201, DOI

Lewandowski, M.; Carmina, M.; Knümann, L.; Sai, M.; Willems, S.; Kasch, T.; Pollinger, J.; Knapp, S.; Marschner, J. A.; Chaikuad, A.; Merk, D. Structure-Guided Design of a Highly Potent Partial RXR Agonist with Superior Physicochemical Properties. J. Med. Chem., 2024, 67, 2152–2164, DOI

Adouvi, G.; Nawa, F.; Ballarotto, M.; Rüger, L. A.; Knümann, L.; Kasch, T.; Arifi, S.; Schubert-Zsilavecz, M.; Willems, S.; Marschner, J. A.; Pabel, J.; Merk, D. Structural Fusion of Natural and Synthetic Ligand Features Boosts RXR Agonist Potency. J. Med. Chem., 2023, 66, 16762–16771, DOI

Sai, M.; Vietor, J.; Kornmayer, M.; Egner, M.; López-García, U.; Höfner, G.; Pabel, J.; Marschner, J.; Wein, T.; Merk, D. Structure-Guided Design of Nurr1 Agonists Derived from the Natural Ligand Dihydroxyindole. J. Med. Chem., 2023,  DOI

Zaienne, D.; Isigkeit, L.; Marschner, J.; Duensing-Kropp, S.; Höfner, G.; Merk, D. Structural Modification of the Natural Product Valerenic Acid Tunes RXR Homodimer Agonism. ChemMedChem, 2023, 18, e202300404 DOI  

Arifi, S.; Marschner, J.; Pollinger, J.; Isigkeit, L.; Heitel, P.; Kaiser, A.; Obeser, L.; Höfner, G.; Proschak, E.; Knapp, S.; Chaikuad, A.; Heering, J.; Merk, D. Targeting the Alternative Vitamin E Metabolite Binding Site Enables Noncanonical PPARγ Modulation. J. Am. Chem. Soc., 2023, DOI

Ballarotto, M.; Willems, S.; Stiller, T.; Nawa, F.; Marschner, J.; Grisoni, F.; Merk, D. De Novo Design of Nurr1 Agonists via Fragment-Augmented Generative Deep Learning in Low-Data Regime. J. Med. Chem., 2023, 66, DOI

Vietor, J.; Gege, C.; Stiller, T.; Busch, R.; Schallmayer, E.; Kohlhof, H.; Höfner, G.; Pabel, J.; Marschner, J.; Merk, D. Development of a Potent Nurr1 Agonist Tool for In Vivo Applications. J. Med. Chem., 2023, 66, 6391–6402. DOI

Adouvi, G.; Isigkeit, L.; Lopez, Ú; Marschner, J.; Schubert-Zsilavecz, M.; Merk, D. Rational design of a new RXR agonist scaffold enabling single-subtype preference for RXRα, RXRβ and RXRγ. J. Med. Chem., 2023, 66, 333–344. DOI

Arifi, S.; Zaienne, D.; Heering, J.; Wein, T.; Zhubi, R.; Chaikuad, A.; Knapp, S.; Marschner, J.; Merk, D. Fragment-based discovery of orphan nuclear receptor Nur77/NGFI-B ligands. Bioorg. Chem., 2022, 106164. DOI

Helmstädter, M.; Schierle, S.; Isigkeit, L.; Proschak, E.; Marschner, J.; Merk, D. Activity screening of fatty acid mimetic drugs identified nuclear receptor agonists. Int. J. Mol. Sci., 2022, 23, 10070. DOI

Zaienne, D.; Arifi, S.; Marschner, J.; Heering, J.; Merk, D. Druggability evaluation of the neuron derived orphan receptor (NOR-1) reveals inverse NOR-1 agonists. ChemMedChem, 2022, 17, e202200259. DOI

Willems, S.; Marschner, J.; Kilu, W.; Faudone, G.; Busch, R.; Duensing-Kropp, S.; Heering, J.; Merk, D. Nurr1 modulation mediates neuroprotective effects of statins. Adv. Sci., 2022, 9(18), 2104640. DOI